{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T22:09:42Z","timestamp":1788041382733,"version":"build-2784847793"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2026,1,31]],"date-time":"2026-01-31T00:00:00Z","timestamp":1769817600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,1,31]],"date-time":"2026-01-31T00:00:00Z","timestamp":1769817600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100003945","name":"Link\u00f6ping University","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100003945","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Endocrinol Invest"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background and Aims<\/jats:title>\n                    <jats:p>Patients with childhood-onset type 1 diabetes (T1D) are at increased risk of developing microvascular complications, including neuropathy and nephropathy. Hormonal dysregulation and markers of atherosclerotic plaque instability and platelet activation may play key roles in the pathogenesis of these complications. The aim of this study was to investigate the impact of hormonal levels on atherosclerotic risk markers and platelet function, as well as to explore the association between diabetic neuropathy and nephropathy in individuals with childhood-onset type 1 diabetes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>In this cross-sectional analysis of a longitudinal cohort, 34 individuals with childhood-onset type 1 diabetes (mean age 27.6\u2009\u00b1\u20094.2\u00a0years; diabetes duration 8.2\u2009\u00b1\u20095.6\u00a0years) were examined. S-IGF-I, long-term HbA1c, micro\/macroalbuminuria, triiodothyronine and thyroxine, S-Cortisol, P-ACTH, P-Renin, sP-Selectin, P-MMP-9, P-TIMP-1, P-Adiponectin, and platelet adhesion to albumin, collagen, and fibrinogen were assessed. An abnormality in nerve conduction tests was defined as diabetic neuropathy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      S-IGF-I was negatively correlated with age (r\u2009=\u2009-0.36,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.007), and with long-term HbA1c (r\u2009=\u2009-0.426,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.019, corrected for age). IGF-I levels in patients diagnosed with clinical neuropathy (n\u2009=\u20096) were lower (123\u2009\u00b1\u200938\u00a0\u00b5g\/L) than in patients without neuropathy (n\u2009=\u200926, 178\u2009\u00b1\u200956\u00a0\u00b5g\/L,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.029). S-IGF-I levels were also lower in patients with nephropathy (n\u2009=\u20097, 122\u2009\u00b1\u200928\u00a0\u00b5g\/L) compared with patients without nephropathy (n\u2009=\u200927, 180\u2009\u00b1\u200960\u00a0\u00b5g\/L,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.02). S-IGF-I was negatively correlated with P-TIMP-1 (r\u2009=\u2009-0.44, p\u2009=\u20090.009), sP-Selectin (r\u2009=\u2009-0.53, p\u2009=\u20090.001), and positively correlated with platelet adhesion to fibrinogen (r\u2009=\u20090.38,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.035). S-free-Triiodothyronine correlated negatively with P-MMP-9, (r\u2009=\u2009-0.46,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.005), and P-MMP-\/P-TIMP-1 ratio (r\u2009=\u2009-0.40,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.018), and P-Adiponectin (r\u2009=\u2009-0.49,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.018). P-Renin correlated negatively with P-Adiponectin (r\u2009=\u2009-0.34,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.045).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Low serum IGF-I levels were associated with the presence of diabetic neuropathy and nephropathy in young adults with type 1 diabetes. Additionally, both IGF-I and S-free-Triiodothyronine levels were linked to changes in platelet activation and atherosclerotic markers, suggesting that hormonal dysregulation may contribute to early vascular complications in this population.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s40618-026-02819-1","type":"journal-article","created":{"date-parts":[[2026,1,31]],"date-time":"2026-01-31T06:34:25Z","timestamp":1769841265000},"page":"1413-1420","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Influence of hormonal levels on atherosclerotic risk markers and platelet activation related to diabetic complications in patients with type 1 diabetes"],"prefix":"10.1007","volume":"49","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4433-1376","authenticated-orcid":false,"given":"Evangelia","family":"Baldimtsi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8732-7361","authenticated-orcid":false,"given":"Bertil","family":"Ekman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3184-0427","authenticated-orcid":false,"given":"Per A.","family":"Whiss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4061-6830","authenticated-orcid":false,"given":"Jeanette","family":"Wahlberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,1,31]]},"reference":[{"issue":"4","key":"2819_CR1","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1007\/s12265-012-9363-x","volume":"5","author":"JK Snell-Bergeon","year":"2012","unstructured":"Snell-Bergeon JK, Nadeau K (2012) Cardiovascular disease risk in young people with type 1 diabetes. J Cardiovasc Transl Res 5(4):446\u2013462","journal-title":"J Cardiovasc Transl Res"},{"issue":"6","key":"2819_CR2","doi-asserted-by":"publisher","first-page":"1018","DOI":"10.2337\/dc15-2308","volume":"39","author":"JL Harding","year":"2016","unstructured":"Harding JL et al (2016) Age-specific trends from 2000-2011 in all-cause and cause-specific mortality in type 1 and type 2 diabetes: a cohort study of more than one million people. Diabetes Care 39(6):1018\u20131026","journal-title":"Diabetes Care"},{"issue":"1\u20132","key":"2819_CR3","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.cca.2005.11.029","volume":"367","author":"S Jacqueminet","year":"2006","unstructured":"Jacqueminet S et al (2006) Elevated circulating levels of matrix metalloproteinase-9 in type 1 diabetic patients with and without retinopathy. Clin Chim Acta 367(1\u20132):103\u2013107","journal-title":"Clin Chim Acta"},{"issue":"8","key":"2819_CR4","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1161\/01.RES.0000070112.80711.3D","volume":"92","author":"R Visse","year":"2003","unstructured":"Visse R, Nagase H (2003) Matrix metalloproteinases and tissue inhibitors of metalloproteinases: structure, function, and biochemistry. Circ Res 92(8):827\u2013839","journal-title":"Circ Res"},{"issue":"4","key":"2819_CR5","doi-asserted-by":"publisher","first-page":"E642","DOI":"10.1210\/jc.2011-2542","volume":"97","author":"RI Pereira","year":"2012","unstructured":"Pereira RI et al (2012) Adiponectin dysregulation and insulin resistance in type 1 diabetes. J Clin Endocrinol Metab 97(4):E642\u2013E647","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"2819_CR6","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1161\/res.90.3.251","volume":"90","author":"ZS Galis","year":"2002","unstructured":"Galis ZS, Khatri JJ (2002) Matrix metalloproteinases in vascular remodeling and atherogenesis: the good, the bad, and the ugly. Circ Res 90(3):251\u2013262","journal-title":"Circ Res"},{"issue":"2","key":"2819_CR7","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1177\/000331970505600208","volume":"56","author":"NP Kadoglou","year":"2005","unstructured":"Kadoglou NP et al (2005) Matrix metalloproteinases and diabetic vascular complications. Angiology 56(2):173\u2013189","journal-title":"Angiology"},{"key":"2819_CR8","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1186\/s12933-015-0195-2","volume":"14","author":"SA Peeters","year":"2015","unstructured":"Peeters SA et al (2015) Plasma levels of matrix metalloproteinase-2, -3, -10, and tissue inhibitor of metalloproteinase-1 are associated with vascular complications in patients with type 1 diabetes: the EURODIAB prospective complications study. Cardiovasc Diabetol 14:31","journal-title":"Cardiovasc Diabetol"},{"issue":"2","key":"2819_CR9","doi-asserted-by":"publisher","DOI":"10.1177\/14791641211002470","volume":"18","author":"N Papadopoulou-Marketou","year":"2021","unstructured":"Papadopoulou-Marketou N et al (2021) Plasma levels of tissue inhibitor of metalloproteinase-1 in patients with type 1 diabetes mellitus associate with early diabetic neuropathy and nephropathy. Diab Vasc Dis Res 18(2):14791641211002470","journal-title":"Diab Vasc Dis Res"},{"issue":"3","key":"2819_CR10","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1093\/cvr\/cvv154","volume":"107","author":"RP McEver","year":"2015","unstructured":"McEver RP (2015) Selectins: initiators of leucocyte adhesion and signalling at the vascular wall. Cardiovasc Res 107(3):331\u2013339","journal-title":"Cardiovasc Res"},{"issue":"4","key":"2819_CR11","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1530\/eje.0.1430505","volume":"143","author":"B Ekman","year":"2000","unstructured":"Ekman B, Nystrom F, Arnqvist HJ (2000) Circulating IGF-I concentrations are low and not correlated to glycaemic control in adults with type 1 diabetes. Eur J Endocrinol 143(4):505\u2013510","journal-title":"Eur J Endocrinol"},{"issue":"12","key":"2819_CR12","doi-asserted-by":"publisher","first-page":"6305","DOI":"10.1210\/jc.2004-0572","volume":"89","author":"CA Hedman","year":"2004","unstructured":"Hedman CA et al (2004) Residual beta-cell function more than glycemic control determines abnormalities of the insulin-like growth factor system in type 1 diabetes. J Clin Endocrinol Metab 89(12):6305\u20136309","journal-title":"J Clin Endocrinol Metab"},{"issue":"8","key":"2819_CR13","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1002\/dmrr.2554","volume":"30","author":"M Palta","year":"2014","unstructured":"Palta M et al (2014) The trajectory of IGF-1 across age and duration of type 1 diabetes. Diabetes Metab Res Rev 30(8):777\u2013783","journal-title":"Diabetes Metab Res Rev"},{"issue":"11","key":"2819_CR14","doi-asserted-by":"publisher","DOI":"10.1111\/acel.13260","volume":"19","author":"BR Gauthier","year":"2020","unstructured":"Gauthier BR et al (2020) Thyroid hormones in diabetes, cancer, and aging. Aging Cell 19(11):e13260","journal-title":"Aging Cell"},{"issue":"1\u20133","key":"2819_CR15","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.jsbmb.2010.04.017","volume":"122","author":"K Simunkova","year":"2010","unstructured":"Simunkova K et al (2010) Adrenocortical function in young adults with diabetes mellitus type 1. J Steroid Biochem Mol Biol 122(1\u20133):35\u201341","journal-title":"J Steroid Biochem Mol Biol"},{"issue":"5","key":"2819_CR16","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdiacomp.2021.107880","volume":"35","author":"JPN Ambinathan","year":"2021","unstructured":"Ambinathan JPN et al (2021) Relationships between inflammation, hemodynamic function and RAAS in longstanding type 1 diabetes and diabetic kidney disease. J Diabetes Complications 35(5):107880","journal-title":"J Diabetes Complications"},{"issue":"1","key":"2819_CR17","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/0165-0173(94)00005-A","volume":"20","author":"DN Ishii","year":"1995","unstructured":"Ishii DN (1995) Implication of insulin-like growth factors in the pathogenesis of diabetic neuropathy. Brain Res Brain Res Rev 20(1):47\u201367","journal-title":"Brain Res Brain Res Rev"},{"issue":"9","key":"2819_CR18","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1111\/j.1464-5491.1995.tb02086.x","volume":"12","author":"IN Migdalis","year":"1995","unstructured":"Migdalis IN et al (1995) Insulin-like growth factor-I and IGF-I receptors in diabetic patients with neuropathy. Diabet Med 12(9):823\u2013827","journal-title":"Diabet Med"},{"issue":"1","key":"2819_CR19","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1016\/j.nbd.2011.04.001","volume":"43","author":"C Morgado","year":"2011","unstructured":"Morgado C et al (2011) Changes in serotoninergic and noradrenergic descending pain pathways during painful diabetic neuropathy: the preventive action of IGF1. Neurobiol Dis 43(1):275\u2013284","journal-title":"Neurobiol Dis"},{"issue":"2","key":"2819_CR20","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1210\/en.2003-0636","volume":"145","author":"JL Fowlkes","year":"2004","unstructured":"Fowlkes JL et al (2004) Regulation of insulin-like growth factor (IGF)-I action by matrix metalloproteinase-3 involves selective disruption of IGF-I\/IGF-binding protein-3 complexes. Endocrinology 145(2):620\u2013626","journal-title":"Endocrinology"},{"issue":"10","key":"2819_CR21","doi-asserted-by":"publisher","first-page":"3187","DOI":"10.2337\/dc12-2226","volume":"36","author":"L Hyllienmark","year":"2013","unstructured":"Hyllienmark L et al (2013) Early electrophysiological abnormalities and clinical neuropathy: a prospective study in patients with type 1 diabetes. Diabetes Care 36(10):3187\u20133194","journal-title":"Diabetes Care"},{"issue":"2","key":"2819_CR22","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1002\/1097-4598(200102)24:2<240::AID-MUS90>3.0.CO;2-2","volume":"24","author":"L Hyllienmark","year":"2001","unstructured":"Hyllienmark L et al (2001) Nerve conduction defects are retarded by tight metabolic control in type I diabetes. Muscle Nerve 24(2):240\u2013246","journal-title":"Muscle Nerve"},{"issue":"3","key":"2819_CR23","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1016\/j.vascn.2005.06.002","volume":"52","author":"AC Eriksson","year":"2005","unstructured":"Eriksson AC, Whiss PA (2005) Measurement of adhesion of human platelets in plasma to protein surfaces in microplates. J Pharmacol Toxicol Methods 52(3):356\u2013365","journal-title":"J Pharmacol Toxicol Methods"},{"issue":"10","key":"2819_CR24","doi-asserted-by":"publisher","first-page":"2285","DOI":"10.2337\/dc10-1303","volume":"33","author":"S Tesfaye","year":"2010","unstructured":"Tesfaye S et al (2010) Diabetic neuropathies: update on definitions, diagnostic criteria, estimation of severity, and treatments. Diabetes Care 33(10):2285\u20132293","journal-title":"Diabetes Care"},{"issue":"2","key":"2819_CR25","doi-asserted-by":"publisher","first-page":"69","DOI":"10.6065\/apem.2015.20.2.69","volume":"20","author":"MS Kim","year":"2015","unstructured":"Kim MS, Lee DY (2015) Insulin-like growth factor (IGF)-I and IGF binding proteins axis in diabetes mellitus. Annals Pediatric Endocrinol Metabolism 20(2):69\u201373","journal-title":"Annals Pediatric Endocrinol Metabolism"},{"key":"2819_CR26","doi-asserted-by":"publisher","DOI":"10.3390\/metabo11110795","author":"M Wysocka-Mincewicz","year":"2021","unstructured":"Wysocka-Mincewicz M et al (2021) Thyroid hormones, peripheral white blood count, and dose of basal insulin are associated with changes in nerve conduction studies in adolescents with type 1 diabetes. Metabolites. https:\/\/doi.org\/10.3390\/metabo11110795","journal-title":"Metabolites"},{"issue":"1","key":"2819_CR27","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1038\/s41572-019-0106-z","volume":"5","author":"P Libby","year":"2019","unstructured":"Libby P et al (2019) Atherosclerosis Nat Rev Dis Primers 5(1):56","journal-title":"Atherosclerosis Nat Rev Dis Primers"},{"key":"2819_CR28","doi-asserted-by":"publisher","DOI":"10.1186\/s40001-023-01431-w","volume":"28","author":"J Liu","year":"2023","unstructured":"Liu J, Pan S, Wang X et al (2023) Role of advanced glycation end products in diabetic vascular injury: molecular mechanisms and therapeutic perspectives. Eur J Med Res 28:553","journal-title":"Eur J Med Res"},{"issue":"22","key":"2819_CR29","doi-asserted-by":"publisher","first-page":"2827","DOI":"10.1161\/01.cir.0000039325.03698.36","volume":"106","author":"LG Bucciarelli","year":"2002","unstructured":"Bucciarelli LG, Wendt T, Qu W, Lu Y, Lalla E, Rong LL, Goova MT, Moser B, Kislinger T, Lee DC, Kashyap Y, Stern DM, Schmidt AM (2002) RAGE blockade stabilizes established atherosclerosis in diabetic apolipoprotein E-null mice. Circulation 106(22):2827\u20132835. https:\/\/doi.org\/10.1161\/01.cir.0000039325.03698.36. (PMID: 12451010)","journal-title":"Circulation"},{"issue":"12","key":"2819_CR30","doi-asserted-by":"publisher","first-page":"108635","DOI":"10.1016\/j.jdiacomp.2023.108635","volume":"37","author":"E Baldimtsi","year":"2023","unstructured":"Baldimtsi E, Whiss PA, Wahlberg J (2023) Systemic biomarkers of microvascular alterations in type 1 diabetes associated neuropathy and nephropathy - a prospective long-term follow-up study. J Diabetes Complications 37(12):108635","journal-title":"J Diabetes Complications"},{"issue":"10","key":"2819_CR31","doi-asserted-by":"publisher","first-page":"1213","DOI":"10.1134\/S0006297919100109","volume":"84","author":"N Gligorijevic","year":"2019","unstructured":"Gligorijevic N, Robajac D, Nedic O (2019) Enhanced platelet sensitivity to IGF-1 in patients with type 2 diabetes mellitus. Biochemistry (Mosc) 84(10):1213\u20131219","journal-title":"Biochemistry (Mosc)"},{"issue":"7","key":"2819_CR32","doi-asserted-by":"publisher","first-page":"1014","DOI":"10.1177\/1076029618774150","volume":"24","author":"PJ Davis","year":"2018","unstructured":"Davis PJ, Mousa SA, Schechter GP (2018) New interfaces of thyroid hormone actions with blood coagulation and thrombosis. Clin Appl Thromb Hemost 24(7):1014\u20131019. https:\/\/doi.org\/10.1177\/1076029618774150","journal-title":"Clin Appl Thromb Hemost"},{"issue":"4","key":"2819_CR33","doi-asserted-by":"publisher","first-page":"634","DOI":"10.1111\/jth.13970","volume":"16","author":"LPB Elbers","year":"2018","unstructured":"Elbers LPB, Fliers E, Cannegieter SC (2018) The influence of thyroid function on the coagulation system and its clinical consequences. J Thromb Haemost 16(4):634\u2013645. https:\/\/doi.org\/10.1111\/jth.13970","journal-title":"J Thromb Haemost"},{"issue":"1","key":"2819_CR34","doi-asserted-by":"publisher","first-page":"T69","DOI":"10.1530\/JME-17-0311","volume":"61","author":"F Hakuno","year":"2018","unstructured":"Hakuno F, Takahashi SI (2018) IGF1 receptor signaling pathways. J Mol Endocrinol 61(1):T69\u2013T86","journal-title":"J Mol Endocrinol"},{"issue":"1","key":"2819_CR35","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/0955-2235(89)90041-0","volume":"1","author":"RC Baxter","year":"1989","unstructured":"Baxter RC, Martin JL (1989) Binding proteins for the insulin-like growth factors: structure, regulation and function. Prog Growth Factor Res 1(1):49\u201368","journal-title":"Prog Growth Factor Res"},{"issue":"1","key":"2819_CR36","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1111\/cen.12296","volume":"81","author":"CA Hedman","year":"2014","unstructured":"Hedman CA et al (2014) Intraperitoneal insulin delivery to patients with type 1 diabetes results in higher serum IGF-I bioactivity than continuous subcutaneous insulin infusion. Clin Endocrinol (Oxf) 81(1):58\u201362","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"9","key":"2819_CR37","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1042\/CS20100400","volume":"120","author":"E Conti","year":"2011","unstructured":"Conti E et al (2011) IGF-1 and atherothrombosis: relevance to pathophysiology and therapy. Clin Sci Lond 120(9):377\u2013402","journal-title":"Clin Sci Lond"},{"issue":"6","key":"2819_CR38","doi-asserted-by":"publisher","first-page":"590","DOI":"10.5551\/jat.3624","volume":"17","author":"M Kamioka","year":"2010","unstructured":"Kamioka M et al (2010) Blockade of renin-angiotensin system attenuates advanced glycation end products-mediated signaling pathways. J Atheroscler Thromb 17(6):590\u2013600","journal-title":"J Atheroscler Thromb"},{"issue":"4","key":"2819_CR39","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1016\/j.stem.2015.07.010","volume":"17","author":"F D\u2019Addio","year":"2015","unstructured":"D\u2019Addio F, La Rosa S, Maestroni A, Jung P, Orsenigo E, Ben Nasr M, Tezza S, Bassi R, Finzi G, Marando A, Vergani A, Frego R, Albarello L, Andolfo A, Manuguerra R, Viale E, Staudacher C, Corradi D, Batlle E, Breault D, Secchi A, Folli F, Fiorina P (2015) Circulating IGF-I and IGFBP3 levels control human colonic stem cell function and are disrupted in diabetic enteropathy. Cell Stem Cell 17(4):486\u2013498. https:\/\/doi.org\/10.1016\/j.stem.2015.07.010","journal-title":"Cell Stem Cell"}],"container-title":["Journal of Endocrinological Investigation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40618-026-02819-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40618-026-02819-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40618-026-02819-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,28]],"date-time":"2026-05-28T07:04:32Z","timestamp":1779951872000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40618-026-02819-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,31]]},"references-count":39,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2026,6]]}},"alternative-id":["2819"],"URL":"https:\/\/doi.org\/10.1007\/s40618-026-02819-1","relation":{},"ISSN":["1720-8386"],"issn-type":[{"value":"1720-8386","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,31]]},"assertion":[{"value":"30 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The research protocol was approved by the Research Ethics Committee, Link\u00f6ping, Sweden, with number Dnr M053-07.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Approval of the research protocol"}},{"value":"Written informed consent was obtained by all subjects before conforms to the provisions of the Declaration of Helsinki.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}